Victory Capital Management Inc. Buys 216,958 Shares of Hologic, Inc. (NASDAQ:HOLX)

Victory Capital Management Inc. raised its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,055,048 shares of the medical equipment provider's stock after purchasing an additional 216,958 shares during the quarter. Victory Capital Management Inc. owned about 2.15% of Hologic worth $361,183,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AE Wealth Management LLC lifted its position in Hologic by 23.7% during the 3rd quarter. AE Wealth Management LLC now owns 5,504 shares of the medical equipment provider's stock worth $382,000 after acquiring an additional 1,056 shares during the period. Commonwealth Equity Services LLC boosted its position in Hologic by 27.8% in the third quarter. Commonwealth Equity Services LLC now owns 74,949 shares of the medical equipment provider's stock valued at $5,201,000 after buying an additional 16,319 shares during the last quarter. Raymond James & Associates increased its holdings in Hologic by 3.0% in the 3rd quarter. Raymond James & Associates now owns 252,013 shares of the medical equipment provider's stock worth $17,490,000 after buying an additional 7,407 shares during the period. Eagle Ridge Investment Management raised its position in Hologic by 0.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 184,452 shares of the medical equipment provider's stock worth $12,801,000 after buying an additional 1,446 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Hologic by 10.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 282,113 shares of the medical equipment provider's stock valued at $19,579,000 after acquiring an additional 25,614 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and boosted their target price for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. StockNews.com downgraded Hologic from a "buy" rating to a "hold" rating in a report on Friday, March 8th. Raymond James boosted their target price on shares of Hologic from $85.00 to $88.00 and gave the company an "outperform" rating in a research note on Friday, February 2nd. UBS Group raised their price target on shares of Hologic from $78.00 to $79.00 and gave the company a "neutral" rating in a research report on Friday, February 2nd. Finally, William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $87.00.

Hologic Price Performance

Hologic stock traded up $0.51 during midday trading on Wednesday, reaching $76.28. The company had a trading volume of 1,423,724 shares, compared to its average volume of 1,750,336. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $86.74. The company has a market capitalization of $17.91 billion, a P/E ratio of 36.01, a P/E/G ratio of 2.59 and a beta of 1.00. The firm's fifty day simple moving average is $76.11 and its 200-day simple moving average is $72.93.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. During the same quarter last year, the business posted $1.07 earnings per share. The business's quarterly revenue was down 5.7% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic, Inc. will post 4.01 EPS for the current year.

Insider Transactions at Hologic

In other news, Director Scott T. Garrett sold 16,441 shares of the firm's stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company's stock, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Charles J. Dockendorff sold 1,465 shares of the business's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Scott T. Garrett sold 16,441 shares of the business's stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders own 1.75% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.